Abstract Details

Title Year 1 Performance of Adveva®, a Patient Support Program (PSP) for Patients Taking MAVENCLAD® (cladribine tablets) for Highly Active Relapsing Remitting Multiple Sclerosis (RRMS) in United Kingdom (UK)

Topic Multiple Sclerosis

Presentation(s) P13 - Poster Session 13 (5:30 PM-6:30 PM)

Poster/Presentation
Number 9-004

Objective To present year 1 results of a patient-support program (PSP) for patients with highly active relapsing-remitting multiple sclerosis (RRMS) taking cladribine tablets (CT).

Background Merck provides a free nurse-led, telephone-based PSP, called adveva®. This supports patients with RRMS in taking medication as prescribed on treatment days and provides dose interpretation advice, clinical appointment reminders, and a home-based phlebotomy service. All potential adverse events are reported to Merck and transcripts are assessed when additional support is needed.

Design/Methods Aggregated and anonymized telephone conversation records were reviewed between December 2017 and August 2018. The analysis determined whether patient-reported adherence, recorded within the PSP data collection system, was achieved and if basic support or additional support was required to achieve the full first year CT cumulative dose of 1.75 mg/kg.

Results 262 patients were registered with adveva® and 186 were registered as fully supported patients (daily phone calls on treatment days). 133 individuals were included in this assessment as they self-reported to have completed both treatment weeks in year 1 at the time of assessment. 130 (98%) patients completed their first-year course as prescribed. The remaining 3 patients received the required cumulative dose of 1.75 mg/kg but at a different time interval to that recommended. 22 (17%) patients required additional support during their treatment days. The additional discussion topics included treatment counselling (41%), dosing advice (30%), and liaising adverse events (30%).

Conclusions All 133 patients included in this assessment self-reported that they achieved the required cumulative 1.75 mg/kg dose of cladribine tablets in their first year of treatment. The support of a proactive telephone-based PSP was of particular value to 22 (17%) patients who required additional support. This is the first report in a post-approval and real world setting that suggests that the majority of patients find cladribine tablets simple-to-take.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
Marco Lyons	No disclosure on file

�鶹��ýӳ��

�鶹��ýӳ��

Abstract Details